Yu, Helena A <br/><br/>
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Apr 2013 
 - 2240-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-12-2246  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Biopsy<br/>CD56 Antigen--analysis<br/>DNA Mutational Analysis--methods<br/>Drug Resistance, Neoplasm--genetics<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride<br/>Female<br/>Gefitinib<br/>Humans<br/>Immunohistochemistry<br/>In Situ Hybridization, Fluorescence<br/>Kaplan-Meier Estimate<br/>Ki-67 Antigen--analysis<br/>Lung--drug effects<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Protein Kinase Inhibitors--therapeutic use<br/>Proto-Oncogene Proteins c-met--genetics<br/>Quinazolines--therapeutic use<br/>Receptor, ErbB-2--genetics